Small Price, Big Upside For New Cancer Treatments By Rexahn And OncBioMune

Mar. 1, 2016 8:19 AM ET
by: Yash Bhatia

Summary

  • Cytotoxic chemotherapy is a hallmark of cancer treatment, but will one day be replaced by targeted, less toxic treatments.
  • Rexahn has two novel oral cancer drugs in development and a new delivery technology that are proving to be safe with signs of efficacy in clinical trials.
  • OncBioMune’s ProscaVax vaccine is proven nontoxic and aiming in a Phase 2 trial to be the first and only treatment for early stage prostate cancer patients.
  • Despite the promising data and drug candidates, both Rexahn and OncBioMune trade with valuations under $75 million.

- Seeking Alpha -

Click here for more information